Scarica l'app Stockscreener
88.21
0.12%
-0.11
Dopo l'orario di chiusura:
88.21
Precedente Chiudi:
$88.32
Aprire:
$89.05
Volume 24 ore:
760.74K
Relative Volume:
0.91
Capitalizzazione di mercato:
$4.93B
Reddito:
$1.34M
Utile/perdita netta:
$-173.66M
Rapporto P/E:
-21.31
EPS:
-4.1385
Flusso di cassa netto:
$-130.49M
1 W Prestazione:
-0.38%
1M Prestazione:
-16.97%
6M Prestazione:
+2.57%
1 anno Prestazione:
+138.86%
Intervallo 1D:
$87.73
$91.24
Intervallo di 1 settimana:
$84.72
$91.24
Portata 52W:
$32.22
$117.88
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
88.21 | 4.95B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
William Blair refreshes its analyst conviction list - TradingView
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Dianthus Therapeutics, Inc. (DNTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dianthus Therapeutics Announces Claseprubart Oral and Poster Presentations at AANEM Annual Meeting - Quiver Quantitative
AXSM Stock Price and Chart — NASDAQ:AXSM - TradingView
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering? - Yahoo Finance
Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run - Yahoo Finance
Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 20,000 Shares - MarketBeat
Dianthus Therapeutics (DNTH) Stock Analysis: Exploring a 39% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares - Stock Titan
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.03 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at JPMorgan Chase & Co. - MarketBeat
JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating - Yahoo Finance
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com South Africa
DNTH: Claseprubart's strong clinical results and pipeline advances are driving rapid growth and expansion - TradingView
Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement - Seeking Alpha
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen - Yahoo Finance
Jupiter Topco LLC Makes New $1.51 Million Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics R&D Head Randhawa Simrat Retains 4,000 Shares After Exercising and Selling Options - Kalkine Media
Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug - Seeking Alpha
Dianthus Therapeutics EVP Simrat Randhawa Executes Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus Therapeutics to Participate in Three Investor Conferences During September - The Manila Times
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case - Seeking Alpha
Dianthus (DNTH) Quarterly Figures: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighStill a Buy? - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Australia
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus (DNTH) Stock: Ends Down by 2.20% at $113.00 at the Close; Market Levels: the Supplied Trading Band Runs From $107.35 to $118.65 at the ClosePre-Earnings Momentum - vinanet.vn
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Director Simon Read Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - Kalkine Media
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133 - Moomoo
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dianthus Therapeutics Inc Azioni (DNTH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CARR EDWARD | CHIEF ACCOUNTING OFFICER |
Sep 17 '26 |
Sale |
101.38 |
20,000 |
2,027,646 |
0 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):